Uptake of Newly Licensed Influenza Vaccine Formulations Among Patients Receiving Chronic Hemodialysis During the 2010/2011 to 2021/2022 Influenza Seasons.

Le résumé fourni par la source

To the Editor: Influenza causes substantial morbidity and mortality in patients with kidney failure. The Centers for Disease Control and Prevention (CDC) has long recommended that patients with kidney failure receive annual influenza vaccination but does not state a preferred vaccine formulation. Recently, the CDC preferentially recommended vaccination with enhanced formulations in persons aged ≥65 years including high-dose inactivated influenza vaccine (hdIIV), adjuvanted inactivated influenza vaccine (aIIV), or recombinant influenza vaccine (RIV) vaccine rather than standard-dose, egg-based, inactivated influenza vaccine (sdeIIV). sdeIIV elicits inferior immunogenicity responses in patients with kidney failure relative to the general population and may be inferior in effectiveness to more novel formulations. Several enhanced influenza vaccine formulations were introduced in the United States starting in 2009, including hdIIV, aIIV, RIV, and cell culture–based (ccIIV). Before 2013, sdeIIV accounted for most influenza vaccination among patients with kidney failure. Otherwise, little is known about utilization of these novel formulations in patients with kidney failure. We sought to evaluate utilization of influenza vaccine formulations from the 2010/2011 to 2021/2022 seasons in a national cohort of patients ≥65 years undergoing hemodialysis.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.